A clinical study of the effect of thymosin in the treatment of liver cell cancer combined with the portal vein branch cancer embolus

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000287

Enrollment

Unknown

Registered

2008-12-31

Start date

2008-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cell cancer combined with the portal vein branch cancer embolus

Interventions

Group A:receive the thymosin treatment after resection of

Group B:Not receive the thymosin treatment after resection of

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The liver cell cancer diagnosis be confirmed by pathology; 2. The liver cell cancer combined with the portal vein branch cancer embolus; 3. The resection of liver cancer been completely.

Exclusion criteria

Exclusion criteria: 1. be complicated with complications include post-operation infection; 2. metastasis cancer been found before giving thymosin; 3. pregnancy; 4. patient received transplantation.

Design outcomes

Primary

Measure	Time frame
Mortality;Relapse rate of cancer;	—

Countries

China

Contacts

Public ContactLunan Yan

yanlunan688@163.com+86 028 81812453

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026